Linette Ruston
Stockport College(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Biochemical and Molecular Research, Computational Drug Discovery Methods, Analytical Chemistry and Chromatography, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure(2006)282 cited
- → Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases(2013)213 cited
- → Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014(2013)204 cited
- → Species differences in drug plasma protein binding(2014)66 cited
- → Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor(2020)58 cited
- → IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies(2020)38 cited
- → Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers(2015)35 cited
- → Activation energies for the decomposition of pharmaceuticals and their application to predicting hydrolytic stability in drug discovery(2010)29 cited
- → Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2(2015)28 cited
- → Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors(2018)26 cited